Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ACTRN12626000585325) titled 'PaedNeoVax - A phase I clinical trial to assess safety and efficacy of personalised mRNA vaccine for children and young adults with high-risk brain tumours' on May 11.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Masking: Open (masking not used)
Assignment: Single group
Type of endpoint: Safety/efficacy
Primary Sponsor: Australian and New Zealand Children's Haematology Oncology Group
Condition:
Brain Cancer
Brain Cancer
Cancer - Brain
Cancer - Children's - Brain
Intervention:
PTX-108 is a personalised mRNA anti-tumour vaccine designed for the treatment of ...